TY - JOUR
T1 - Photodynamic therapy for the treatment of choroidal neovascularization secondary to rubella retinopathy
AU - Wang, Leo K.
AU - Kansal, Sukesh
AU - Pulido, Jose S.
N1 - Funding Information:
Supported in part by NIH Core Grant EY01792 and an unrestricted grant from Research to Prevent Blindness Inc., New York, New York.
PY - 2002/11/1
Y1 - 2002/11/1
N2 - PURPOSE: To describe a patient for whom photodynamic therapy was used to treat subfoveal choroidal neovascularization secondary to rubella retinopathy. DESIGN: Interventional case report. METHODS: A 36-year-old man with subfoveal choroidal neovascularization secondary to rubella retinopathy was treated with photodynamic therapy using verteporfin. Outcome was followed up with subsequent fundus examinations, fluorescein angiography, and evaluations of best-corrected visual acuity. RESULTS: Two treatments of photodynamic therapy using verteporfin resulted in involution of the neovascular membrane, resolution of subretinal hemorrhage, and improvement in best-corrected visual acuity from 20/200 to 20/60 2 months after the second treatment. Owing to recurrence of active choroidal neovascularization, the patient required two more treatments of photodynamic therapy in the next 6 months, after which his best-corrected visual acuity was restored to 20/60. CONCLUSION: Photodynamic therapy may be an effective treatment for subfoveal choroidal neovascularization secondary to rubella retinopathy.
AB - PURPOSE: To describe a patient for whom photodynamic therapy was used to treat subfoveal choroidal neovascularization secondary to rubella retinopathy. DESIGN: Interventional case report. METHODS: A 36-year-old man with subfoveal choroidal neovascularization secondary to rubella retinopathy was treated with photodynamic therapy using verteporfin. Outcome was followed up with subsequent fundus examinations, fluorescein angiography, and evaluations of best-corrected visual acuity. RESULTS: Two treatments of photodynamic therapy using verteporfin resulted in involution of the neovascular membrane, resolution of subretinal hemorrhage, and improvement in best-corrected visual acuity from 20/200 to 20/60 2 months after the second treatment. Owing to recurrence of active choroidal neovascularization, the patient required two more treatments of photodynamic therapy in the next 6 months, after which his best-corrected visual acuity was restored to 20/60. CONCLUSION: Photodynamic therapy may be an effective treatment for subfoveal choroidal neovascularization secondary to rubella retinopathy.
UR - http://www.scopus.com/inward/record.url?scp=0036847089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036847089&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(02)01647-1
DO - 10.1016/S0002-9394(02)01647-1
M3 - Article
C2 - 12429271
AN - SCOPUS:0036847089
SN - 0002-9394
VL - 134
SP - 790
EP - 792
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -